Simupharma Announces $2M Seed Funding Round via CARTA to Scale the Personal Health Data Capsule.
We are thrilled to announce that Simupharma has officially opened a $2M USD seed funding round. This capital raise, administered as a Simple Agreement for Future Equity (SAFE) through the CARTA platform, marks a pivotal moment in our mission to revolutionize individualized health informatics. This funding will test and then launch the first Simupharma product, a personal heath intelligence system, brought to life on any mobile device.
Since our inception, Simupharma has worked to bridge the gap between fragmented medical data and actionable, real-time health simulations. This funding will be directly channeled into scaling our core infrastructure—specifically the “Personal Health Data Capsule.” By expanding our engineering and clinical data science teams, we aim to accelerate the deployment of our unified system to healthcare providers and research institutions globally.
“This seed round isn’t just about capital; it’s about velocity,” says the Simupharma leadership team. “With the support of our investors through the transparent and efficient CARTA ecosystem, we are positioned to turn the proprietary ‘Personal Health Data Capsule’ from a technical breakthrough into a clinical standard.”
Investors interested in joining our journey to redefine personal health intelligence for optimized longitudinal care can contact Simupharma leadership here. Together, we are building a future where every patient can understand, engage with, and best utilize their own health information. More transparency. Personal control. More informed decisions. Optimal individualized care. That’s Simupharma.